ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion

Pigment Cell and Melanoma Research

Volumn 27, Issue 6, 2014, Pages 1138-1148

  Gangemi, Rosaria ^a   Amaro, Adriana ^a   Gino, Alice ^a   Barisione, Gaia ^a   Fabbi, Marina ^a   Pfeffer, Ulrich ^a   Brizzolara, Antonella ^a   Queirolo, Paola ^a   Salvi, Sandra ^a   Boccardo, Simona ^a   Gualco, Marina ^a   Spagnolo, Francesco ^a   Jager, Martine J ^b   Mosci, Carlo ^c   Rossello, Armando ^d   Ferrini, Silvano ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c GALLIERA HOSPITAL   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

ADAM10; ADAM17; C Met; Gene expression; Invasion; Uveal melanoma

Indexed keywords

ADAM10 ENDOPEPTIDASE; ADAM17 PROTEIN; METALLOPROTEINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAM10 PROTEIN, HUMAN; MEMBRANE PROTEIN; MET PROTEIN, HUMAN; SECRETASE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; PROGRESSION FREE SURVIVAL; RISK FACTOR; TUMOR INVASION; UVEA MELANOMA; ANIMAL; BLOOD; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MELANOMA; METABOLISM; PATHOLOGY; SOLUBILITY; TUMOR CELL LINE; UVEA TUMOR;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MELANOMA; MEMBRANE PROTEINS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MET; RISK FACTORS; SOLUBILITY; UVEAL NEOPLASMS;

EID: 84911373803     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12306     Document Type: Article

References (44)

1. Amaro, A., Mirisola, V., Angelini, G. et al. (2013). Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity. Eur. J. Cancer 49, 3353-3365.
2. Buder, K., Gesierich, A., Gelbrich, G., and Goebeler, M. (2013). Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med. 2, 674-686.
3. Coupland, S.E., Lake, S.L., Zeschnigk, M., and Damato, B.E. (2013). Molecular pathology of uveal melanoma. Eye 27, 230-242.
4. Cree, I.A. (2000). Cell cycle and melanoma-two different tumors from the same cell type. J Pathol. 191, 112-114.
5. Damato, B. (2010). Does ocular treatment of uveal melanoma influence survival? Br. J. Cancer 103, 285-290.
6. De Waard-Siebinga, I., Blom, D.J., Griffioen, M., Schrier, P.I., Hoogendoorn, E., Beverstock, G., Danen, E.H., and Jager, M.J. (1995). Establishment and characterization of a uveal-melanoma cell line. Int. J. Cancer 62, 155-161.
7. Dono, M., Angelini, G., Cecconi, M. et al. (2014). Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br. J. Cancer 110, 1058-1065.
8. Economou, M.A., All-Ericsson, C., Bykov, V., Girnita, L., Bartolazzi, A., Larsson, O., and Seregard, S. (2005). Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest. Ophthalmol. Vis. Sci. 46, 4372-4375.
9. Foveau, B., Ancot, F., Leroy, C., Petrelli, A., Reiss, K., Vingtdeux, V., Giordano, S., Fafeur, V., and Tulasne, D. (2009). Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol. Biol. Cell 20, 2495-2507.
10. Fu, L., Guo, W., Liu, B., Sun, L., Bi, Z., Zhu, L., Wang, X., Liu, B., Xie, Q., and Li, K. (2013). Shedding of c-Met ectodomain correlates with c-Met expression in non-small cell lung cancer. Biomarkers 18, 126-135.
11. Gangemi, R., Mirisola, V., Barisione, G. et al. (2012). Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression. PLoS ONE 7, e29989.
12. Griewank, K.G., Murali, R., Schilling, B. et al. (2013). TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br. J. Cancer 109, 497-501.
13. Harbour, J.W. (2012). The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res. 25, 171-181.
14. Harbour, J.W., Roberson, E.D., Anbunathan, H., Onken, M.D., Worley, L.A., and Bowcock, A.M. (2013). Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 45, 133-135.
15. Hendrix, M.J., Seftor, E.A., Seftor, R.E., Kirschmann, D.A., Gardner, L.M., Boldt, H.C., Meyer, M., Pe'er, J., and Folberg, R. (1998). Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am. J. Pathol. 152, 855-863.
16. Irizarry, R.A., Bolstad, B.M., Collin, F., Cope, L.M., Hobbs, B., and Speed, T.P. (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15.
17. Jackson, A.L., and Linsley, P.S. (2010). Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 9, 57-67.
18. Kenny, P.A. (2007). TACE: a new target in epidermal growth factor receptor dependent tumors. Differentiation 9, 800-808. Review.
19. Ko, S.Y., Lin, S.C., Wong, Y.K., Liu, C.J., Chang, K.W., and Liu, T.Y. (2007). Increase of disintegrin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett. 245, 33-43.
20. Laurent, C., Valet, F., Planque, N. et al. (2011). High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 71, 666-674.
21. Lee, S.B., Schramme, A., Doberstein, K. et al. (2010). ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol. 130, 763-773.
22. Luyten, G.P., Naus, N.C., Mooy, C.M., Hagemeijer, A., Kan-Mitchell, J., Van Drunen, E., Vuzevski, V., De Jong, P.T., and Luider, T.M. (1996). Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int. J. Cancer 66, 380-387.
23. Mallikarjuna, K., Pushparaj, V., Biswas, J., and Krishnakumar, S. (2007). Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-MET in uveal melanoma: an immunohistochemical study. Curr. Eye Res. 32, 281-290.
24. Martin, M., Masshofer, L., Temming, P. et al. (2013). Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933-936.
25. Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., and Comoglio, P.M. (2004). Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 6, 61-73.
26. Nuti, E., Casalini, F., Avramova, S.I. et al. (2010). Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models. J. Med. Chem. 53, 2622-2635.
27. Onken, M.D., Ehlers, J.P., Worley, L.A., Makita, J., Yokota, Y., and Harbour, J.W. (2006). Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. Cancer Res. 66, 4602-4609.
28. Peruzzi, B., and Bottaro, D.P. (2006). Targeting the c-MET signaling pathway in cancer. Clin. Cancer Res. 12, 3657-3660.
29. Rosso, O., Piazza, T., Bongarzone, I., Rossello, A., Mezzanzanica, D., Canevari, S., Orengo, A.M., Puppo, A., Ferrini, S., and Fabbi, M. (2007). The ALCAM shedding by the metalloprotease ADAM17/TACE is involved in motility of ovarian carcinoma cells. Mol. Cancer Res. 5, 1246-1253.
30. Saftig, P., and Reiss, K. (2011). The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur. J. Cell Biol. 90, 527-535.
31. Schelter, F., Kobuch, J., Moss, M.L., Becherer, J.D., Comoglio, P.M., Boccaccio, C., Krüger, A. (2010). A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J. Biol. Chem. 285, 26335-26340.
32. Singh, A.D., Bergman, L., and Seregard, S. (2005). Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 18, 75-84.
33. Stella, G.M., Benvenuti, S., and Comoglio, P.M. (2010). Targeting the MET oncogene in cancer and metastases. Expert Opin. Investig. Drugs 19, 1381-1394.
34. Surriga, O., Rajasekhar, V.K., Ambrosini, G., Dogan, Y., Huang, R., and Schwartz, G.K. (2013). Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model. Mol. Cancer Ther. 12, 2817-2826.
35. Topcu-Yilmaz, P., Kiratli, H., Saglam, A., Söylemezoglu, F., and Hascelik, G. (2010). Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 20, 126-132.
36. Triozzi, P.L., Eng, C., and Singh, A.D. (2008). Targeted therapy for uveal melanoma. Cancer Treat. Rev. 34, 247-258.
37. Trusolino, L., Bertotti, A., and Comoglio, P.M. (2010). MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 11, 834-848.
38. Tschentscher, F., Hüsing, J., Hölter, T. et al. (2003). Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res. 63, 2578-2584.
39. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
40. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
41. Wiesner, T., Obenauf, A.C., Murali, R. et al. (2011). Germline mutations in BAP1 predispose to melanocytic tumors. Nat. Genet. 43, 1018-1021.
42. Wu, X., Zhou, J., Rogers, A.M., Jänne, P.A., Benedettini, E., Loda, M., and Hodi, F.S. (2012). c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential. Melanoma Res. 22, 123-132.
43. Xu, Q., Liu, X., Chen, W., and Zhang, Z. (2010). Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference. J Transl Med. 8, 136.
44. Zhou, B.B., Peyton, M., He, B. et al. (2006). Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10, 39-50.